Industry wind direction 丨 good policy is densely introduced, medical device is re -activated

In September, the medical device sector, which has been adjusting in the past year, has ushered in many favorable policies, especially for innovative medical devices, and its innovation kinetic energy is activated again.

On September 3, 2022, the National Medical Security Bureau issued the "Answer to the National Medical Security Bureau on the Suggestion No. 4955 of the Fifth Session of the 13th National People's Congress". For collection, the current penetration rate of consumables involved is low, there are technical barriers, and the market size is relatively small.

The article pointed out that we must focus on improving the innovative medical device platform hanging mechanism, emphasizing that optimizing the process, timely response, and transparentness when hanging the network, aiming to reduce corporate related costs, and help new medical devices participate in market transactions smoothly. At the same time, the establishment of a market -oriented price formation mechanism must not only reflect the product value and supply and demand relationship, but also comprehensively consider factors such as the price, clinical efficacy, health income, and the use of similar products in international products to form innovative medical equipment. Reasonable price. For innovative medical devices, it is difficult to implement the method of bringing in clinical use and difficulty in using clinical use and temporary use. The Medical Insurance Bureau clearly pointed out that in addition to the purchase of centralized band volume, a certain market provides space for innovative products to develop markets.

Photo source: Photo Network-500510556

On September 8th, the National Medical Insurance Bureau issued the "Notice on the Price Governance of Oral Planting Medical Services and Consumption Price Governance", which requires the three -level public medical institution to adjust to the interval within 4,500 yuan/piece. Compared with the average price of medical services, the price is reduced by 25%, and the overall decrease is mild. Secondly, notifying the separation of power consumption and marketization through consumables, prompting competition to focus on the quality of medical services. On September 27, the National Organization of High -value Medical Consumption Office issued the "Public Announcement of the National Orthopedic spine consumables for centralized band procurement". In the past, spinal surgery still had a lot of room for improvement in domestic penetration. After this price reduction, spinal surgery was expected to achieve rapid growth.

The analysis of Guolian Securities pointed out that the current policy surface of the medical insurance sector has not changed greatly. Under the position of funding, valuation and performance stable, it is optimistic about the third quarter. And the faucet in the track and then enjoy the valuation premium, it is difficult to continue in the current market environment. On the other hand, pharmaceutical stock selection cannot be completely separated from the track. At present, it should be selected in the short -term non -integrated, broad and stable track to choose enterprises with brand influence and can obtain larger market share. At present, the stock selection of stocks from three segmentation is the new medical infrastructure, serious medical services, and globalization opportunities. These sectors have stable demand and less disturbance of the epidemic. The leading performance is expected to maintain stability, the profitability has continued to improve, and the valuation has been adjusted to a reasonable position.

Here, by integrating the latest research report information of more than 10 brokerage firms such as Tianfeng, Anxin, Guoxin, it brings 4 companies to fans and friends for reference only.

1. Weigao Orthopedic

The company is the leading domestic orthopedic medical device provider. The product layout is comprehensive and the source of innovation and development is long. Since its establishment, the company has been deeply cultivating orthopedic implantation in the medical device market. Through self -research and mergers and acquisitions, it has achieved the layout of spine, trauma, and joint product lines. One of the companies with complete product categories, leading scale, and market competitiveness. The company relies on Weigao Group to position the domestic orthopedic mid -to -high -end market at the beginning of its establishment, and continues to strengthen R & D investment. It has both upstream materials research and development capabilities and the foundation of underlying technological innovation. The price reduction pressure of collectives will also be forced to innovate and upgrade enterprises, and companies with real innovation capabilities are expected to stand out. (Oriental Securities)

2. Opening medical treatment

Kaikai Medical has been in the field of mid-to-high-end color Doppler ultrasound for many years. The high-end color Doppler ultrasound technology of 60 platforms is strong, and core technologies are still iterating; soft mirror products continue to iterate, high-end products HD-550 have high cost-effective advantages, and the variety of mirror varieties continues Expansion has been registered with bronchoscopic mirrors, optical enlarged endoscopy, ultrasonic endoscopy, stiffness endoscopy and fine mirror, etc., and the competitiveness has been significantly improved. Ultrasound is approved one after another, and ultrasound in the vascular vascular is expected to be approved in the second half of this year, ensuring that long -term performance is sustainable. (Western Securities)

3. Weili Medical

Under the market recovery situation after the epidemic, the company focuses on breaking the cost -effectiveness and quality improvement of overseas customers' technical cooperation projects and large -scale customized products. More than 20 items such as Cardinal and Medeline are expected to enter the redeem period in the next few years. In addition, in order to better services and tap potential customers, the company reforms the export strategy to formulate front movement plan at the beginning of the year. It will conduct the first batch of pilots and overseas branches in the United States and Europe. Advantages, technological advantages and capacity advantages have gradually expanded the OEM/ODM market, and continued to provide growth momentum for overseas business growth. (Huaxi Securities)

4. Yuyue Medical

There are many company products and wide coverage. As of 2021, there are more than 600 product categories, nearly 10,000 product specifications, and scope of blood pressure monitoring, body temperature monitoring, surgical equipment, respiratory and oxygen, first aid, ophthalmology and other fields.Constantly launch innovative products and high -end products.On the one hand, the structure of multi -category products can respond randomly in market demand fluctuations, on the other hand, it continues to provide new growth points for the company, stimulate vitality, and effectively maintain the company's overall competitiveness in the medical device industry.(Northeast Securities) Daily Economic News

- END -